US4406906A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Cerebral therapeutic agent and its use
Assignee: Bayer AG
•
Filing: 1982-02-05
•
Granted: 1983-09-27
•
Expires: 2002-02-05
Abstract
Abstract The invention provides pharmaceutical compositions and medicaments, useful for the treatment of cerebral disorders, wherein the active compound is 1,4-dihydro-2,6-dimethyl-4-(3'-nitrophenyl)-pyridine-3-(β-methoxyethyl ester)-5-(isopropyl ester). Also included in the invention are methods for the use of said compositions and medicaments.
Inventors
- 👤 Horst Meyer
- 👤 Friedrich Bossert
- 👤 Stanislav Kazda
- 👤 Friedrich Hoffmeister
- 👤 Wulf Vater
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 16:25
CPC Classifications
C; C07; C07D; C07D211/00; C07D211/04; C07D211/80; C07D211/84; C07D211/90; A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/44; A61P; A61P25/00; A61P25/28; A61P9/00; A61P9/08
Claims Analysis
Total Claims: 5
Claim 1
Independent Claim
58 words
A method of combating pathologically reduced cerebral functions and performance weaknesses, cerebral insufficiency and disorders in cerebral circulation and metabolism in warm-blooded animals which comprises administering to the said animals a cerebral specific effective amount for treating said conditions of 1,4dihydro-2,6dimethyl-4-(3'-nitrophenyl)-pyridino-3-(β-methoxyethyl ester)-5-isopropyl ester either alone or in admixture with a diluent or in the form of a medicament.
Claim 2
Independent Claim
58 words
A method of combating pathologically reduced cerebral functions and performance weaknesses, cerebral insufficiency and disorders in cerebral circulation and metabolism in warm-blooded animals which comprises administering to the said animals a cerebral specific effective amount for treating said conditions of 1,4dihydro-2,6dimethyl-4-(3'-nitrophenyl)-pyridino-3-(β-methoxyethyl ester)-5-isopropyl ester either alone or in admixture with a diluent or in the form of a medicament.
Claim 3
Dependent Claim
44 words
A method according to claim 1 in which the active compound is administered intravenously in an amount of 0.0001 to 0.5 mg per kg body weight per day, or enterally in an amount of 0.001 to 1 mg per kg body weight per day.
Claim 4
Dependent Claim
43 words
A method according to claim 1, in which the compound is administered intravenously in an amount of 0.001 to 0.1 mg per kg body weight per day, or enterally in an amount of 0.01 to 0.5 mg per kg body weight per day.
Claim 5
Dependent Claim
16 words
A method according to claim 1 or 2 in which the active compound is administered orally.
References Cited (Backward Citations)
US3799934A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1986-09-26 | 1987-03-28 | 1987-09-27 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1990-09-26 | 1991-03-28 | 1991-09-27 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1994-09-26 | 1995-03-28 | 1995-09-27 | $7700.00 | Window Closed / Lapsed |